The price-to-earnings ratio for Boston Scientific Corp (NYSE: BSX) is above average at 83.68x. The 36-month beta value for BSX is also noteworthy at 0.78. There are mixed opinions on the stock, with 23 analysts rating it as a “buy,” 7 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for BSX is 1.47B, and at present, short sellers hold a 0.71% of that float. The average trading volume of BSX on February 25, 2025 was 5.43M shares.
BSX) stock’s latest price update
The stock of Boston Scientific Corp (NYSE: BSX) has decreased by -0.10 when compared to last closing price of 104.49. Despite this, the company has experienced a -1.62% fall in its stock price over the last five trading sessions. globenewswire.com reported 2025-02-24 that Dublin, Feb. 24, 2025 (GLOBE NEWSWIRE) — The “Balloon Catheters Patent Landscape Report” has been added to ResearchAndMarkets.com’s offering.
BSX’s Market Performance
Boston Scientific Corp (BSX) has experienced a -1.62% fall in stock performance for the past week, with a 2.71% rise in the past month, and a 15.57% rise in the past quarter. The volatility ratio for the week is 1.47%, and the volatility levels for the past 30 days are at 1.53% for BSX. The simple moving average for the last 20 days is -0.10% for BSX stock, with a simple moving average of 22.73% for the last 200 days.
Analysts’ Opinion of BSX
Many brokerage firms have already submitted their reports for BSX stocks, with Deutsche Bank repeating the rating for BSX by listing it as a “Buy.” The predicted price for BSX in the upcoming period, according to Deutsche Bank is $108 based on the research report published on January 10, 2025 of the current year 2025.
Goldman gave a rating of “Buy” to BSX, setting the target price at $90 in the report published on May 30th of the previous year.
BSX Trading at 6.90% from the 50-Day Moving Average
After a stumble in the market that brought BSX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.59% of loss for the given period.
Volatility was left at 1.53%, however, over the last 30 days, the volatility rate increased by 1.47%, as shares surge +2.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.66% upper at present.
During the last 5 trading sessions, BSX fell by -1.62%, which changed the moving average for the period of 200-days by +43.89% in comparison to the 20-day moving average, which settled at $104.50. In addition, Boston Scientific Corp saw 16.87% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BSX starting from Zane Ellen M, who sale 13,586 shares at the price of $104.23 back on Feb 24 ’25. After this action, Zane Ellen M now owns 34,944 shares of Boston Scientific Corp, valued at $1,416,134 using the latest closing price.
JEFFREY B MIRVISS, the Officer of Boston Scientific Corp, proposed sale 4,675 shares at $104.25 during a trade that took place back on Feb 24 ’25, which means that JEFFREY B MIRVISS is holding shares at $487,369 based on the most recent closing price.
Stock Fundamentals for BSX
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.67 for the gross margin
The net margin for Boston Scientific Corp stands at 0.11. The total capital return value is set at 0.09. Equity return is now at value 9.03, with 4.97 for asset returns.
Based on Boston Scientific Corp (BSX), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at 0.31. The debt to equity ratio resting at 0.51. The interest coverage ratio of the stock is 9.34.
Currently, EBITDA for the company is 2.6 billion with net debt to EBITDA at 2.78. When we switch over and look at the enterprise to sales, we see a ratio of 9.84. The receivables turnover for the company is 6.55for trailing twelve months and the total asset turnover is 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.08.
Conclusion
In summary, Boston Scientific Corp (BSX) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
